Xydalba
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Dalbavancin
- Made by
- AbbVie Deutschland GmbH & Co. KG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Dalbavancin). It describes the substance, not this exact product.
Dalbavancin is an antibacterial drug [see Microbiology (12.4)].
Following administration of a single 1,000 mg dose in healthy subjects, 20% of the dose was excreted in feces through 70 days post dose.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-28
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | AbbVie Deutschland GmbH & Co. KG |
|---|---|
| Active substance | Dalbavancin |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01XA04 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2015-02-19 |
| Last updated by the regulator | 2025-11-20 |
| EMA product number | EMEA/H/C/002840 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).